Endocrine therapy is a cancer treatment that works by blocking or lowering the hormones that fuel certain tumors. It’s most commonly used for breast cancer and prostate cancer, where hormones like estrogen and testosterone act as growth signals for cancer cells. Unlike chemotherapy, which attacks rapidly dividing cells throughout the body, endocrine therapy targets the hormonal environment that keeps specific cancers alive.
How Endocrine Therapy Works
Some cancers depend on hormones the way a fire depends on oxygen. Breast cancer cells often carry estrogen receptors on their surface, and when estrogen binds to those receptors, it triggers the cell to grow and divide. Prostate cancer cells behave similarly with testosterone. Endocrine therapy either cuts off the hormone supply or blocks the cancer cell’s ability to use it.
Doctors test a tumor’s hormone sensitivity before recommending this treatment. For breast cancer, a biopsy sample is stained and examined under a microscope. If at least 1% of tumor cells show hormone receptors, the cancer is classified as hormone receptor-positive and the patient is a candidate for endocrine therapy. Roughly 70-80% of breast cancers fall into this category.
Endocrine Therapy for Breast Cancer
Three main classes of drugs are used, each taking a different approach to the same problem.
Estrogen receptor blockers work like a key jammed in a lock. The drug attaches to estrogen receptors on cancer cells, physically preventing estrogen from connecting and delivering its growth signal. Estrogen remains fully present in the body, but it can’t reach the tumor. Tamoxifen is the most well-known drug in this category and has been used for decades.
Aromatase inhibitors take the opposite approach: instead of blocking the receptor, they stop the body from making estrogen in the first place. After menopause, estrogen is primarily produced by an enzyme called aromatase, which converts other hormones into estrogen. Aromatase inhibitors shut down that conversion process. Because premenopausal women still produce estrogen from their ovaries (which doesn’t depend on aromatase in the same way), these drugs are typically reserved for postmenopausal patients or used alongside ovarian suppression therapy.
Estrogen receptor degraders go a step further. Rather than simply blocking the receptor, they cause the receptor itself to break down and disappear from the cancer cell’s surface. This eliminates the docking site entirely. In January 2023, the FDA approved the first oral drug in this newer class, elacestrant, for patients whose cancer has progressed after prior endocrine therapy.
Endocrine Therapy for Prostate Cancer
Prostate cancer’s fuel is testosterone and other androgens. Androgen deprivation therapy, or ADT, is the most common first-line hormone treatment for prostate cancer. It works by interrupting the chain of signals between the brain and the testicles that drives testosterone production.
One approach uses drugs that overstimulate the pituitary gland’s hormone receptors. This sounds counterintuitive, but constant overstimulation actually causes the gland to shut down, like an alarm that’s been ringing so long it burns out. The result is a dramatic drop in testosterone. A notable quirk of these drugs: they initially cause a temporary testosterone spike called a “flare” before levels crash. Doctors sometimes prescribe a short course of additional medication to counteract this surge.
A newer class of drugs blocks the same pituitary receptors directly, preventing the signal from being sent at all. These don’t cause the testosterone flare, which makes them preferable for some patients. One of these, relugolix, is taken as a daily pill rather than an injection, which many patients find more convenient.
How Effective Is It?
For hormone receptor-positive breast cancer, the numbers are significant. Five years of tamoxifen reduces breast cancer recurrence by about 40% over the first decade. Aromatase inhibitors perform even better, cutting recurrence by roughly 50%. The reductions in breast cancer death are about 30% for tamoxifen and 40% for aromatase inhibitors, and these mortality benefits continue beyond the ten-year mark.
For patients who complete an initial five years and then continue with an aromatase inhibitor for five more years, recurrence drops by an additional 27% compared to stopping treatment. The mortality benefit of this extended phase is smaller and less statistically certain, which is why the decision to continue beyond five years involves weighing the added protection against ongoing side effects.
How Long Treatment Lasts
The standard minimum course of endocrine therapy for breast cancer is five years. For many patients, guidelines now recommend extending to a full ten years. Premenopausal women who start on tamoxifen are generally offered the option to continue it for ten years total. Postmenopausal women who complete five years of tamoxifen may switch to an aromatase inhibitor to reach the ten-year mark, or continue tamoxifen for the full duration.
For prostate cancer, duration varies more widely depending on stage and risk level. Some patients receive ADT for a defined period alongside radiation, while others stay on it indefinitely for advanced disease.
Common Side Effects
Because endocrine therapy suppresses major hormones, the side effects often mirror what happens during natural hormone decline. For breast cancer patients, this means menopausal symptoms: hot flashes, night sweats, joint stiffness, fatigue, mood changes, and vaginal dryness. Tamoxifen can also slightly increase the risk of blood clots and uterine changes. Aromatase inhibitors, by contrast, don’t carry those risks but are harder on bones.
Bone thinning is a particular concern with aromatase inhibitors. Because estrogen helps maintain bone density, blocking its production accelerates bone loss. Clinical guidelines recommend a bone density scan before starting an aromatase inhibitor and annual scans throughout treatment. Bone density is measured using a T-score: anything below -2.5 indicates osteoporosis. Scores between -1 and -2.5 signal early bone loss. Weight-bearing exercise, calcium, and vitamin D are standard protective measures, and some patients need bone-strengthening medication.
For prostate cancer patients on ADT, low testosterone causes hot flashes, reduced muscle mass, weight gain, fatigue, sexual dysfunction, and mood changes. Long-term use also raises the risk of bone thinning and metabolic changes like increased blood sugar and cholesterol.
Fertility Considerations
Since endocrine therapy is often prescribed to younger, premenopausal patients who may want children in the future, the question of fertility planning comes up frequently. These drugs can harm a developing fetus, so pregnancy during treatment is not safe. After stopping therapy, the general recommendation is to wait at least three months before attempting conception, which accounts for the time needed for the drugs to clear the body.
Some patients choose to pause endocrine therapy temporarily to have children and then resume it afterward. A major clinical trial (called POSITIVE) studied this approach and found it to be a viable option for women with hormone-responsive breast cancer, though the decision involves careful discussion about individual recurrence risk and timing.